Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00117754|
Recruitment Status : Completed
First Posted : July 8, 2005
Last Update Posted : February 21, 2007
Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum.
Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.
|Condition or disease||Intervention/treatment||Phase|
|Tinea Capitis||Drug: Terbinafine hydrochloride||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||720 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis|
|Study Start Date :||July 2004|
|Estimated Study Completion Date :||April 2006|
- Complete cure (negative mycology and clinical cure) rate at Week 10
- Clinical cure rate at Week 10
- Mycological cure rate at Week 10
- Safety of terbinafine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00117754
|United States, New Jersey|
|East Hanover, New Jersey, United States, 07936|